Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Boston Common Asset Management LLC

Boston Common Asset Management LLC lessened its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 11.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 135,312 shares of the medical research company's stock after selling 17,220 shares during the quarter. Boston Common Asset Management LLC's holdings in Edwards Lifesciences were worth $9,807,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in EW. Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $610,895,000. Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $555,939,000. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $213,844,000. Finally, Marshall Wace LLP lifted its position in shares of Edwards Lifesciences by 55.7% during the 4th quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock valued at $430,367,000 after acquiring an additional 2,079,642 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday, May 13th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Citigroup reiterated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Stock Up 0.5%

EW stock traded up $0.36 during trading on Friday, reaching $78.09. The stock had a trading volume of 9,048,502 shares, compared to its average volume of 5,194,532. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $45.81 billion, a P/E ratio of 11.20, a PEG ratio of 4.82 and a beta of 1.12. The firm has a fifty day moving average price of $73.35 and a 200 day moving average price of $72.41.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the business posted $0.66 EPS. The firm's revenue was up 6.2% compared to the same quarter last year. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president now owns 33,496 shares in the company, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,442 shares of company stock worth $4,025,799 in the last quarter. 0.34% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.